Combination chemotherapy in the treatment of follicular low-grade lymphoma

Vicki A. Morrison, Bruce A. Peterson

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


The therapeutic approach to patients with follicular low-grade non-Hodgkin's lymphoma is controversial and has varied over a wide spectrum. A "watch and wait" approach in asymptomatic patients has been taken in some studies. In other series, single agent therapy with alkylating agents as cy-clophosphamide or chlorambucil has been employed. Response rates including complete responses are high, but relapses inevitably occur. Three-drug combination chemotherapy regimens consisting of cyclophosphamide, vincristine, and prednisone (CVP) have been utilized, in addition to more intensive regimens consisting of four or more drugs. Although responses are commonly achieved, there is no consistent survival advantage conferred by these more aggressive regimens. However, the remission duration may be prolonged in some subsets of patients as those with follicular mixed lymphoma. Due to the prolonged natural history of follicular low-grade lymphoma, a long period of follow-up is necessary to adequately evaluate the impact of a therapeutic regimen on remission duration and overall survival. Future trials may employ more aggressive therapy in combination with growth factors or biologic response modifiers in an effort to improve the outcome of patients with follicular low-grade lymphoma.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalLeukemia and Lymphoma
Issue numberS1
StatePublished - 1993

Bibliographical note

Funding Information:
Supported in part by the Lymphoma Research Project of the Minnesota Medical Foundation Address for correspondence: Vicki A. Morrison, M.D., Veterans Affairs Medical Center, Section of HematologylOncology 11 1E. One Veterans Drive, Minneapolis, MN 55417 612-725-2016 (Facsimile)


  • Combination chemotherapy
  • Follicular lymphoma
  • Low-grade lymphoma


Dive into the research topics of 'Combination chemotherapy in the treatment of follicular low-grade lymphoma'. Together they form a unique fingerprint.

Cite this